Trials of venous thromboembolism prevention

Lancet

Volumn 370, Issue 9591, 2007, Pages 915-917

  Norrie, John ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CELECOXIB; DABIGATRAN ETEXILATE; ENOXAPARIN; EVEROLIMUS; INSULIN SENSITIZING AGENT; PACLITAXEL; PIOGLITAZONE; RAPAMYCIN; ROSIGLITAZONE; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ARTICLE; DRUG ELUTING STENT; FOLLOW UP; HUMAN; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; VENOUS THROMBOEMBOLISM;

EID: 34548565926     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61425-1     Document Type: Note

References (12)

1. Eriksson B., Dahl O., Rosencher N., et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370 (2007) 949-956
2. Committee for Proprietary Medicinal Products (CPMP). Points to consider on clinical investigation of medicinal products for prophylaxis of intra- and post-operative venous thromboembolic risk (June, 2000). http://www.emea.europa.eu/pdfs/human/ewp/070798en.pdf (accessed Aug 14, 2007).
3. Kassai B., Shah N., Leizororvicza A., Cucherat M., Gueyffier F., and Boissel J. The true treatment benefit is unpredictable in clinical trials using surrogate outcome measured with diagnostic tests. J Clin Epidemiol 58 (2005) 1042-1051
4. O'Donnell M., and Kearon C. Thromboembolism prevention in ischaemic stroke. Lancet 369 (2007) 1413-1415
5. Goodacre S., Sampson F., Stevenson M., et al. Measurement of the clinical and cost effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis. Health Technol Assess 10 (2006) 1-168
6. Rodgers A., and MacMahon S. Systematic underestimation of treatment effects as a result of diagnostic test inaccuracy: implications for the interpretation and design of thrombo-prophylaxis trials. Thromb Haemost 73 (1995) 167-171
7. Thabut G., Estellat C., Boutron I., Samana C., and Ravaud P. Methodological issues in trials assessing primary prophylaxis of venous thrombo-embolism. Eur Heart J 27 (2006) 227-236
8. Committee for Proprietary Medicinal Products (CPMP). Draft guideline on clinical investigation of medicinal products for prophylaxis of high intra- and post-operative venous thromboembolic risk. November, 2006. http://www.emea.europa.eu/pdfs/human/ewp/70798en.pdf (accessed Aug 14, 2007).
9. Committee for Proprietary Medicinal Products (CPMP). Recommendation for the need for revision of the guideline on clinical investigation of medicinal products for prophylaxis of high intra- and post-operative venous thromboembolic risk (November, 2005). http://www.emea.europa.eu/pdfs/human/ewp/34066005en.pdf (accessed Sept 10, 2007).
10. Committee for Proprietary Medicinal Products (CPMP). Points to consider on adjustment for baseline covariates (May, 2003). http://www.emea.europa.eu/pdfs/human/ewp/286399en.pdf (accessed Aug 14, 2007).
11. Geerts W., Heit J., Clagett G., et al. Prevention of venous thromboembolism. Chest 119 (2001) 132S-175S
12. Boudes P. The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee. Contemp Clin Trials 27 (2006) 432-440